Zymeworks Inc Stock News

Shares of Zymeworks Inc. ZYME, +1.89% rallied 1.5% in morning trading Friday, after the biopharmaceutical company said it rejected the "unsolicited, opportunistic, non-binding" $10.50-per-share buyout

Zymeworks shares have fallen, but the pipeline remains intact. Moreover, a special situation is brewing.

Over the past 3 months, 4 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company

Upgrades According to Tudor Pickering, the prior rating for ProPetro Holding Corp (NYSE:PUMP) was changed from Hold to Buy. In the first quarter, ProPetro Holding showed an EPS of $0.11, compared to $

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (NYSE:ZYME ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Neil Klompas - Chief Operating Officer Ke

April saw the worst monthly performance for the NASDAQ since November of 2008 when the country was in the depths of the financial crisis. What will the month of May bring for investors?

Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.

New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.